Chlorin Conjugates in Photodynamic Chemotherapy for Triple-Negative Breast Cancer

被引:1
|
作者
Isaac-Lam, Meden F. [1 ]
机构
[1] Purdue Univ Northwest, Dept Chem & Phys, Westville, IN 46391 USA
关键词
photodynamic therapy; anti-cancer treatment; chemotherapy; photosensitizers; drug combinations; NANOMOLAR CONCENTRATIONS; MOLECULAR-MECHANISMS; THERAPY; METHOTREXATE; DOXORUBICIN; 5-FLUOROURACIL; ENHANCEMENT; COMBINATION; INHIBITION; CISPLATIN;
D O I
10.3390/ph17050576
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Breast cancer (BC) is the most common type of cancer in women and the number of new cases in the US is still increasing each year. Triple-negative breast cancer (TNBC), which comprises 15-20% of all breast cancer, is a heterogeneous disease and is considered the most aggressive type of breast cancer due to the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expressions for treatments. Traditional chemotherapy is the standard protocol for the treatment of TNBC. Toxicity and multidrug resistance are major drawbacks to chemotherapy. The lack of molecular targets and poor prognosis for TNBC prompts an urgent need to discover novel therapeutic strategies to improve clinical outcomes and quality of life for patients. Photodynamic therapy (PDT) or light treatment is a binary anti-cancer procedure that uses a photosensitizer (PS) that, upon light activation, produces cytotoxic oxygen species, destroying tumor cells. PDT is minimally invasive and can be repeated a few times without accumulating significant toxicity in the surrounding tissues. The primary goal of this study was to investigate in vitro photodynamic chemotherapy as a ternary combination therapy using our synthesized photosensitizers (chlorin-vitamin conjugates and their corresponding indium complexes) co-treated with known chemotherapeutic agents (taxol, doxorubicin, cisplatin, fluorouracil, or methotrexate) in the presence of light and determine the optimum conditions as a pre-clinical study of an enhanced tumoricidal effect against TNBC. Our results indicated that the best combination for an effective chemophotodynamic effect involves a ternary treatment of the indium complex of the chlorin-lipoic acid conjugate (InCLA) co-treated with taxol, which exhibited strong synergism at the nanomolar concentration when combined in the presence of visible light irradiation. Other ternary combinations containing taxol with a synergistic anti-tumor effect against TNBC include chlorin-pantothenic acid (CPA) and chlorin-biotin (CBTN) conjugates. Several other ternary combinations containing InCLA, CBTN, and CPA with either cisplatin, fluorouracil, or methotrexate were identified to generate a synergistic or additive effect. The light dosage remained constant, but the dosages of photosensitizers and chemotherapy drugs were varied to obtain the lowest possible concentration for the desired effect. The synergistic, additive or antagonistic effects of the drug combinations were determined based on the Chou-Talalay method, with InCLA-taxol having the lowest combination index (CI) of 0.25. Fluorescence and transmission electron microscopy (TEM) images provided evidence of apoptosis as the preferred mode of cell death. Our study demonstrated the combination of PDT and chemotherapy as a potential treatment option for TNBC patients.
引用
收藏
页数:31
相关论文
共 50 条
  • [11] Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer
    Locatelli, Marzia A.
    Curigliano, Giuseppe
    Eniu, Alexandru
    BREAST CARE, 2017, 12 (03) : 152 - 158
  • [12] Pembrolizumab plus chemotherapy in triple-negative breast cancer
    Masuda, Jun
    Ozaki, Yukinori
    Hara, Fumikata
    Kitano, Shigehisa
    Takano, Toshimi
    LANCET, 2021, 398 (10294): : 24 - 24
  • [13] Antibody Drug Conjugates for Triple-Negative Breast Cancer: Targeting Positive in the Negative
    Bardia, Aditya
    ONCOLOGIST, 2017, 22 : S3 - S3
  • [14] Dual stimuli-activatable versatile nanoplatform for photodynamic therapy and chemotherapy of triple-negative breast cancer
    Xu, Jie
    Lai, Yi
    Wang, Fengyang
    Zou, Zhifeng
    Pei, Renjun
    Yu, Haijun
    Xu, Zhiai
    CHINESE CHEMICAL LETTERS, 2023, 34 (12)
  • [15] Dual stimuli-activatable versatile nanoplatform for photodynamic therapy and chemotherapy of triple-negative breast cancer
    Jie Xu
    Yi Lai
    Fengyang Wang
    Zhifeng Zou
    Renjun Pei
    Haijun Yu
    Zhiai Xu
    ChineseChemicalLetters, 2023, 34 (12) : 450 - 458
  • [16] Photodynamic therapy potential of cobalt phthalocyanine in triple-negative breast cancer
    Dogan, Sifa
    Ince, Mine
    Sogutlu, Fatma
    Avci, Cigir Biray
    Ozel, Derya
    Yurt, Fatma
    POLYHEDRON, 2023, 245
  • [17] Platinum-based chemotherapy in triple-negative breast cancer
    Sirohi, B.
    Arnedos, M.
    Popat, S.
    Ashley, S.
    Nerurkar, A.
    Walsh, G.
    Johnston, S.
    Smith, I. E.
    ANNALS OF ONCOLOGY, 2008, 19 (11) : 1847 - 1852
  • [18] Platinum-Based Chemotherapy in Triple-Negative Breast Cancer
    Villarreal-Garza, C.
    Bouganim, N.
    Khalaf, D.
    Clemons, M.
    Kassam, F.
    Enright, K.
    Verma, S.
    Myers, J.
    Dent, R.
    CANCER RESEARCH, 2011, 71
  • [19] Triple-Negative Breast Cancer Role of Specific Chemotherapy Agents
    Isakoff, Steven J.
    CANCER JOURNAL, 2010, 16 (01): : 53 - 61
  • [20] Activity of dasatinib with chemotherapy in triple-negative breast cancer cells
    Tryfonopoulos, D.
    O'Donovan, N.
    Corkery, B.
    Clynes, M.
    Crown, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)